Literature DB >> 20600491

Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.

James J Sejvar1, Katrin S Kohl, Jane Gidudu, Anthony Amato, Nandini Bakshi, Roger Baxter, Dale R Burwen, David R Cornblath, Jan Cleerbout, Kathryn M Edwards, Ulrich Heininger, Richard Hughes, Najwa Khuri-Bulos, Rudolf Korinthenberg, Barbara J Law, Ursula Munro, Helena C Maltezou, Patricia Nell, James Oleske, Robert Sparks, Priscilla Velentgas, Patricia Vermeer, Max Wiznitzer.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20600491     DOI： 10.1016/j.vaccine.2010.06.003

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  142 in total

1.  Guillain-Barré Syndrome in India: population-based validation of the Brighton criteria.

Authors:  Farrah J Mateen; David R Cornblath; Hamid Jafari; Russell T Shinohara; Devendra Khandit; Bina Ahuja; Sunil Bahl; Roland W Sutter
Journal:  Vaccine       Date:  2011-10-11       Impact factor: 3.641

2.  Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.

Authors:  Tanya R Myers; Michael M McNeil; Carmen S Ng; Rongxia Li; Paige W Lewis; Maria V Cano
Journal:  Vaccine       Date:  2017-03-03       Impact factor: 3.641

3.  Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.

Authors:  Sharon K Greene; Melisa Rett; Eric S Weintraub; Lingling Li; Ruihua Yin; Anthony A Amato; Doreen T Ho; Sarah I Sheikh; Bruce H Fireman; Matthew F Daley; Edward A Belongia; Steven J Jacobsen; Roger Baxter; Tracy A Lieu; Martin Kulldorff; Claudia Vellozzi; Grace M Lee
Journal:  Am J Epidemiol       Date:  2012-05-11       Impact factor: 4.897

4.  Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.

Authors:  Rohit P Ojha; Bradford E Jackson; Joseph E Tota; Tabatha N Offutt-Powell; Karan P Singh; Sejong Bae
Journal:  Hum Vaccin Immunother       Date:  2013-09-06       Impact factor: 3.452

5.  Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study.

Authors:  Christian Hoppe; Patrick Obermeier; Susann Muehlhans; Maren Alchikh; Lea Seeber; Franziska Tief; Katharina Karsch; Xi Chen; Sindy Boettcher; Sabine Diedrich; Tim Conrad; Bron Kisler; Barbara Rath
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

6.  Implementation and Evaluation of Guillain-Barré Syndrome Surveillance in Puerto Rico during the 2016 Zika Virus Epidemic.

Authors:  Chelsea G Major; Emilio Dirlikov; Nicole A Medina; Roberta Lugo-Robles; Desiree Matos; Jorge Muñoz-Jordán; Candimar Colón-Sánchez; Myriam García-Negrón; Marangely Olivero-Segarra; Graciela Malavé-González; Dana L Thomas; Carlos A Luciano; Stephen H Waterman; James Sejvar; Tyler M Sharp; Brenda Rivera-García
Journal:  P R Health Sci J       Date:  2018-12       Impact factor: 0.705

7.  Clinical Features of Guillain-Barré Syndrome With vs Without Zika Virus Infection, Puerto Rico, 2016.

Authors:  Emilio Dirlikov; Chelsea G Major; Nicole A Medina; Roberta Lugo-Robles; Desiree Matos; Jorge L Muñoz-Jordan; Candimar Colon-Sanchez; Myriam Garcia; Marangely Olivero-Segarra; Graciela Malave; Gloria M Rodríguez-Vega; Dana L Thomas; Stephen H Waterman; James J Sejvar; Carlos A Luciano; Tyler M Sharp; Brenda Rivera-García
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

8.  Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.

Authors:  Ingrid B Rabe; Elaine R Miller; Marc Fischer; Susan L Hills
Journal:  Vaccine       Date:  2014-12-09       Impact factor: 3.641

9.  Template protocol for clinical trials investigating vaccines--focus on safety elements.

Authors:  Jan Bonhoeffer; Egeruan B Imoukhuede; Grace Aldrovandi; Novilia S Bachtiar; Eng-Soon Chan; Soju Chang; Robert T Chen; Rohini Fernandopulle; Karen L Goldenthal; James D Heffelfinger; Shah Hossain; Indira Jevaji; Ali Khamesipour; Sonali Kochhar; Mamodikoe Makhene; Elissa Malkin; David Nalin; Rebecca Prevots; Ranjan Ramasamy; Sarah Sellers; Johan Vekemans; Kenneth B Walker; Pam Wilson; Virginia Wong; Khalequz Zaman; Ulrich Heininger
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

10.  Hyperbaric oxygen therapy in a patient with Guillain-Barré syndrome receiving mechanical ventilation.

Authors:  Lisha Song; Baopeng Xing; Weimin Yang; Haifeng Li
Journal:  Diving Hyperb Med       Date:  2020-09-30       Impact factor: 0.887
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.